Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Pharmaceuticals	1.31B	1.37B	1.29B	1.13B	1.31B
Pharmaceuticals Growth	-4.59%	6.35%	14.40%	-13.91%	-
Total	1.31B	1.37B	1.29B	1.13B	1.31B
Total Growth	-4.59%	6.35%	14.40%	-13.91%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Mainland China	1.26B	1.32B	1.25B	1.07B	1.17B
Mainland China Growth	-4.18%	5.65%	16.01%	-8.29%	-
Other Countries/Regions	45.47M	53.30M	41.91M	51.80M	136.57M
Other Countries/Regions Growth	-14.69%	27.18%	-19.09%	-62.07%	-
Total	1.31B	1.37B	1.29B	1.13B	1.31B
Total Growth	-4.59%	6.35%	14.40%	-13.91%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 18, 2026

Data Sources Report a data error